Adelene Perkins - Infinity Pharmaceuticals Chairman of The Board, CEO and Pres

INFIDelisted Stock  USD 0.13  0.01  7.14%   

Chairman

Ms. Adelene Q. Perkins serves as Chairman of the Board, Chief Executive Officer of the Company. She was Chairman of the Board, President, Chief Executive Officer of Infinity Pharmaceuticals Inc. She has served as our President and Chief Executive Officer since January 2010, President and Chief Business Officer from October 2008 through December 2009 and as our Executive Vice President and Chief Business Officer between September 2006 and October 2008. Ms. Perkins served as Executive Vice President of IPI from February 2006 until its merger with DPI in September 2006 and Chief Business Officer of IPI from June 2002 until the DPI merger. Prior to joining IPI, Ms. Perkins served as Vice President of Business and Corporationrationrate Development of TransForm Pharmaceuticals, Inc., a private pharmaceutical company, from 2000 to 2002. From 1992 to 1999, Ms. Perkins held various positions at Genetics Institute, most recently serving as Vice President of Emerging Business and General Manager of the DiscoverEase business unit. Ms. Perkins has served as a director of the Biotechnology Industry Organization since 2012, a director of Project Hope, a notforprofit social services company since 2013, a director of the Massachusetts Life Sciences Center, a quasipublic agency of the Commonwealth of Massachusetts, since 2014, a director of the Massachusetts Biotechnology Council, a notforprofit organization, since 2014, and a director of Padlock Therapeutics, a privately held biopharmaceutical company since 2015. From 1985 to 1992, Ms. Perkins held a variety of positions at Bain Company, a strategy consulting firm since 2017.
Age 63
Tenure 7 years
Professional MarksMBA
Phone617 453 1000
Webhttps://www.infi.com
Perkins received a B.S. in Chemical Engineering from Villanova University and an M.B.A. from Harvard Business School.

Infinity Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.607) % which means that it has lost $0.607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (35.2135) %, meaning that it created substantial loss on money invested by shareholders. Infinity Pharmaceuticals' management efficiency ratios could be used to measure how well Infinity Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Infinity Pharmaceuticals currently holds 917 K in liabilities with Debt to Equity (D/E) ratio of 0.13, which may suggest the company is not taking enough advantage from borrowing. Infinity Pharmaceuticals has a current ratio of 4.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Infinity Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 3 records

CHAIRMAN Age

MD FACPEdgewise Therapeutics
64
Harlan MDLyra Therapeutics
71
Sean DPHILCytomX Therapeutics
57
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts. Infinity Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Infinity Pharmaceuticals (INFI) is traded on NASDAQ Exchange in USA and employs 30 people.

Management Performance

Infinity Pharmaceuticals Leadership Team

Elected by the shareholders, the Infinity Pharmaceuticals' board of directors comprises two types of representatives: Infinity Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Infinity. The board's role is to monitor Infinity Pharmaceuticals' management team and ensure that shareholders' interests are well served. Infinity Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Infinity Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Melissa Hackel, Vice President - Finance
Seth JD, Chief VP
Stephane Peluso, Chief Officer
MD Ilaria, Chief Officer
Jayne Kauffman, Sr Coordinator
Adelene Perkins, Chairman of The Board, CEO and Pres
MD JD, Pres Treasurer

Infinity Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Infinity Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Other Consideration for investing in Infinity Stock

If you are still planning to invest in Infinity Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Infinity Pharmaceuticals' history and understand the potential risks before investing.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing